Comparing Auspex Pharmaceuticals (ASPX) & Its Peers
Auspex Pharmaceuticals (NASDAQ: ASPX) is one of 291 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Auspex Pharmaceuticals to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.
This is a breakdown of recent ratings and target prices for Auspex Pharmaceuticals and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auspex Pharmaceuticals Competitors||1176||3523||12063||248||2.67|
Institutional and Insider Ownership
49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Auspex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auspex Pharmaceuticals Competitors||-5,345.53%||-158.67%||-35.84%|
Valuation & Earnings
This table compares Auspex Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Auspex Pharmaceuticals Competitors||$290.27 million||$35.99 million||68.43|
Auspex Pharmaceuticals’ rivals have higher revenue and earnings than Auspex Pharmaceuticals. Auspex Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Auspex Pharmaceuticals rivals beat Auspex Pharmaceuticals on 6 of the 8 factors compared.
About Auspex Pharmaceuticals
Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington’s disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Receive News & Ratings for Auspex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.